Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable, stage III non-small-cell lung cancer

Marina C. Garassino; Luis Paz-Ares; Rina Hui; Corinne Faivre-Finn; Alex Spira; David Planchard; Mustafa Ozguroglu; Davey Daniel; David Vicente; Shuji Murakami; Corey Langer; Suresh Senan; David Spigel; Anna Ryden; Yiduo Zhang; Cathy O'Brien; Phillip A. Dennis; Scott J. Antonia

doi:10.2217/fon-2020-1102

Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable, stage III non-small-cell lung cancer

Marina C. Garassino, Luis Paz-Ares, Rina Hui, Corinne Faivre-Finn, Alex Spira, David Planchard, Mustafa Ozguroglu, Davey Daniel, David Vicente, Shuji Murakami, Corey Langer, Suresh Senan, David Spigel, Anna Ryden, Yiduo Zhang, Cathy O'Brien, Phillip A. Dennis, Scott J. Antonia

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Article › peer-review

Abstract

Aim: We retrospectively investigated the impact of tumor PD-L1 expression and prior chemoradiotherapy (CRT)-related variables on patient-reported outcomes (PROs) from PACIFIC. Patients & methods: PACIFIC was a Phase III study of durvalumab versus placebo after CRT in patients with unresectable, stage III non-small-cell lung cancer. If available, pre-CRT tumor tissue was tested for PD-L1 tumor-cell expression, scored at prespecified (25%) and post-hoc (1%) cut-offs. PROs were assessed using EORTC QLQ C30/-LC13. Results: Similar to the intent-to-treat (ITT) population, most PROs remained stable over time across PD-L1 and CRT subgroups, with few clinically relevant differences between treatment arms. Time to deterioration was generally similar to the ITT population. Conclusion: Neither PD-L1 expression nor prior CRT-related variables influenced PROs with durvalumab therapy.

Original language	English
Pages (from-to)	1165-1184
Number of pages	20
Journal	Future Oncology
Volume	17
Issue number	10
Early online date	15 Feb 2021
DOIs	https://doi.org/10.2217/fon-2020-1102
Publication status	Published - 1 Apr 2021

Keywords

durvalumab
patient-reported outcomes
programmed cell death ligand-1

Research Beacons, Institutes and Platforms

Manchester Cancer Research Centre

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2217/fon-2020-1102

Our research as part of the international PACIFIC trial, led to the approval of a new treatment (Durvalumab) which improves progression free and overall survival in Stage III Non-small cell lung cancer (NSCLC)
Faivre-Finn, C. (Corresponding participant)
Impact: Health and wellbeing

Cite this

Garassino, M. C., Paz-Ares, L., Hui, R., Faivre-Finn, C., Spira, A., Planchard, D., Ozguroglu, M., Daniel, D., Vicente, D., Murakami, S., Langer, C., Senan, S., Spigel, D., Ryden, A., Zhang, Y., O'Brien, C., Dennis, P. A., & Antonia, S. J. (2021). Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable, stage III non-small-cell lung cancer. Future Oncology, 17(10), 1165-1184. https://doi.org/10.2217/fon-2020-1102

@article{4986ec775f7f4c91a74d7ac781be8042,

title = "Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable, stage III non-small-cell lung cancer",

abstract = "Aim: We retrospectively investigated the impact of tumor PD-L1 expression and prior chemoradiotherapy (CRT)-related variables on patient-reported outcomes (PROs) from PACIFIC. Patients & methods: PACIFIC was a Phase III study of durvalumab versus placebo after CRT in patients with unresectable, stage III non-small-cell lung cancer. If available, pre-CRT tumor tissue was tested for PD-L1 tumor-cell expression, scored at prespecified (25%) and post-hoc (1%) cut-offs. PROs were assessed using EORTC QLQ C30/-LC13. Results: Similar to the intent-to-treat (ITT) population, most PROs remained stable over time across PD-L1 and CRT subgroups, with few clinically relevant differences between treatment arms. Time to deterioration was generally similar to the ITT population. Conclusion: Neither PD-L1 expression nor prior CRT-related variables influenced PROs with durvalumab therapy.",

keywords = "durvalumab, patient-reported outcomes, programmed cell death ligand-1",

author = "Garassino, {Marina C.} and Luis Paz-Ares and Rina Hui and Corinne Faivre-Finn and Alex Spira and David Planchard and Mustafa Ozguroglu and Davey Daniel and David Vicente and Shuji Murakami and Corey Langer and Suresh Senan and David Spigel and Anna Ryden and Yiduo Zhang and Cathy O'Brien and Dennis, {Phillip A.} and Antonia, {Scott J.}",

note = "Funding Information: This study (ClinicalTrials.gov: NCT02125461) was funded by AstraZeneca. C Faivre-Finn is supported by a grant from the NIHR Manchester Biomedical Research Centre. MC Garassino has received advisory fees from AstraZeneca, Bristol-Myers Squibb, Clovis Oncology, Genentech/Roche, Eli Lilly, Trovagene, Vortex Biosciences, Amgen and Celgene; speaker's bureau fees from Merck; and research funding from Eli Lilly, Genentech/Roche, Astex Pharmaceuticals, Clovis Oncology, Bristol-Myers Squibb, AstraZeneca, Threshold Pharmaceuticals, Array BioPharma, Celgene, AbbVie, Astellas Pharma, Corvus Pharmaceuticals and Spectrum Pharmaceuticals. L Paz-Ares has received advisory fees from MSD, Bristol-Myers Squibb, Roche, AstraZeneca, Eli Lilly, Merck, Novartis, Amgen, Incyte, Takeda, Blueprint, Bayer, PharmaMar and Ipsen; speaker's bureau fees from MSD, Bristol-Myers Squibb, Roche, AstraZeneca and Eli Lilly; travel, accommodations and expenses from MSD, Roche and AstraZeneca; and is an editorial board member for Altum Sequencing and Genomica. R Hui has received advisory fees from AstraZeneca, Bristol-Myers Squibb, Eli Lilly,MSD, Novarfuture tis and Roche. Publisher Copyright: {\textcopyright} 2021 Marina Chiara Garassino.",

year = "2021",

month = apr,

day = "1",

doi = "10.2217/fon-2020-1102",

language = "English",

volume = "17",

pages = "1165--1184",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Future Medicine ",

number = "10",

}

Garassino, MC, Paz-Ares, L, Hui, R, Faivre-Finn, C, Spira, A, Planchard, D, Ozguroglu, M, Daniel, D, Vicente, D, Murakami, S, Langer, C, Senan, S, Spigel, D, Ryden, A, Zhang, Y, O'Brien, C, Dennis, PA & Antonia, SJ 2021, 'Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable, stage III non-small-cell lung cancer', Future Oncology, vol. 17, no. 10, pp. 1165-1184. https://doi.org/10.2217/fon-2020-1102

TY - JOUR

T1 - Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable, stage III non-small-cell lung cancer

AU - Garassino, Marina C.

AU - Paz-Ares, Luis

AU - Hui, Rina

AU - Faivre-Finn, Corinne

AU - Spira, Alex

AU - Planchard, David

AU - Ozguroglu, Mustafa

AU - Daniel, Davey

AU - Vicente, David

AU - Murakami, Shuji

AU - Langer, Corey

AU - Senan, Suresh

AU - Spigel, David

AU - Ryden, Anna

AU - Zhang, Yiduo

AU - O'Brien, Cathy

AU - Dennis, Phillip A.

AU - Antonia, Scott J.

N1 - Funding Information: This study (ClinicalTrials.gov: NCT02125461) was funded by AstraZeneca. C Faivre-Finn is supported by a grant from the NIHR Manchester Biomedical Research Centre. MC Garassino has received advisory fees from AstraZeneca, Bristol-Myers Squibb, Clovis Oncology, Genentech/Roche, Eli Lilly, Trovagene, Vortex Biosciences, Amgen and Celgene; speaker's bureau fees from Merck; and research funding from Eli Lilly, Genentech/Roche, Astex Pharmaceuticals, Clovis Oncology, Bristol-Myers Squibb, AstraZeneca, Threshold Pharmaceuticals, Array BioPharma, Celgene, AbbVie, Astellas Pharma, Corvus Pharmaceuticals and Spectrum Pharmaceuticals. L Paz-Ares has received advisory fees from MSD, Bristol-Myers Squibb, Roche, AstraZeneca, Eli Lilly, Merck, Novartis, Amgen, Incyte, Takeda, Blueprint, Bayer, PharmaMar and Ipsen; speaker's bureau fees from MSD, Bristol-Myers Squibb, Roche, AstraZeneca and Eli Lilly; travel, accommodations and expenses from MSD, Roche and AstraZeneca; and is an editorial board member for Altum Sequencing and Genomica. R Hui has received advisory fees from AstraZeneca, Bristol-Myers Squibb, Eli Lilly,MSD, Novarfuture tis and Roche. Publisher Copyright: © 2021 Marina Chiara Garassino.

PY - 2021/4/1

Y1 - 2021/4/1

N2 - Aim: We retrospectively investigated the impact of tumor PD-L1 expression and prior chemoradiotherapy (CRT)-related variables on patient-reported outcomes (PROs) from PACIFIC. Patients & methods: PACIFIC was a Phase III study of durvalumab versus placebo after CRT in patients with unresectable, stage III non-small-cell lung cancer. If available, pre-CRT tumor tissue was tested for PD-L1 tumor-cell expression, scored at prespecified (25%) and post-hoc (1%) cut-offs. PROs were assessed using EORTC QLQ C30/-LC13. Results: Similar to the intent-to-treat (ITT) population, most PROs remained stable over time across PD-L1 and CRT subgroups, with few clinically relevant differences between treatment arms. Time to deterioration was generally similar to the ITT population. Conclusion: Neither PD-L1 expression nor prior CRT-related variables influenced PROs with durvalumab therapy.

AB - Aim: We retrospectively investigated the impact of tumor PD-L1 expression and prior chemoradiotherapy (CRT)-related variables on patient-reported outcomes (PROs) from PACIFIC. Patients & methods: PACIFIC was a Phase III study of durvalumab versus placebo after CRT in patients with unresectable, stage III non-small-cell lung cancer. If available, pre-CRT tumor tissue was tested for PD-L1 tumor-cell expression, scored at prespecified (25%) and post-hoc (1%) cut-offs. PROs were assessed using EORTC QLQ C30/-LC13. Results: Similar to the intent-to-treat (ITT) population, most PROs remained stable over time across PD-L1 and CRT subgroups, with few clinically relevant differences between treatment arms. Time to deterioration was generally similar to the ITT population. Conclusion: Neither PD-L1 expression nor prior CRT-related variables influenced PROs with durvalumab therapy.

KW - durvalumab

KW - patient-reported outcomes

KW - programmed cell death ligand-1

U2 - 10.2217/fon-2020-1102

DO - 10.2217/fon-2020-1102

M3 - Article

SN - 1479-6694

VL - 17

SP - 1165

EP - 1184

JO - Future Oncology

JF - Future Oncology

IS - 10

ER -

Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable, stage III non-small-cell lung cancer

Abstract

Keywords

Research Beacons, Institutes and Platforms

UN SDGs

Access to Document

Fingerprint

Impacts

Our research as part of the international PACIFIC trial, led to the approval of a new treatment (Durvalumab) which improves progression free and overall survival in Stage III Non-small cell lung cancer (NSCLC)

Cite this